Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. It was developed by Bluebird Bio...
21 KB (1,463 words) - 07:11, 6 August 2024
company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia...
15 KB (1,408 words) - 21:01, 17 October 2024
There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the...
35 KB (6,225 words) - 08:38, 21 March 2025
There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the...
75 KB (7,679 words) - 18:35, 17 March 2025
and mortality 7%. The best results are with very young people. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the...
41 KB (4,621 words) - 16:57, 13 January 2025
making it the most expensive drug ever. In May, the EMA approved betibeglogene autotemcel (Zynteglo) for treating beta thalassemia for people twelve years...
179 KB (18,436 words) - 06:46, 7 April 2025
RMAT designated drugs include the novel CAR-T therapy Kymriah and betibeglogene autotemcel for beta thalassemia. As of 31 March 2021, 62 requests for RMAT...
29 KB (1,621 words) - 17:30, 19 February 2025
lymphoma Beremagene geperpavec (Vyjuvek): treatment of wounds. Betibeglogene autotemcel (Zynteglo): treatment for beta thalassemia Brexucabtagene autoleucel...
11 KB (857 words) - 23:07, 7 March 2025
(INN) Betaxon betazole (INN) bethanechol (INN) betiatide (INN) betibeglogene autotemcel (USAN, INN) Betimol Betnesol Betnovate Betoptic Pilo Betoptic S...
15 KB (631 words) - 06:34, 16 February 2025
B06AX01 Crizanlizumab B06AX02 Betibeglogene autotemcel B06AX03 Voxelotor B06AX04 Mitapivat B06AX05 Exagamglogene autotemcel "ATC (Anatomical Therapeutic...
1,011 bytes (217 words) - 03:43, 23 December 2024
arylsulfatase A (ARSA) gene (European approval granted 2020). Betibeglogene autotemcel (branded as Zynteglo) for the treatment of transfusion-dependent...
78 KB (8,788 words) - 19:06, 6 August 2024